Vertex Ventures HC

Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.

TORL BioTherapeutics is a clinical-stage biopharmaceutical business focused on creating innovative, antibody-based medicines to improve the lives of cancer patients. They are developing a comprehensive pipeline of innovative preclinical ADCs and mAb in oncologic diseases with high unmet medical needs.

Allay is pioneering a new category of ultra-sustained pain therapeutics to transform post-surgical pain management and recuperation for patients and physicians. Allay’s proprietary technology platform combines validated non-opioid analgesics and biopolymers to create dissolvable therapeutics to deliver pain relief within a targeted site over weeks—an order of magnitude greater than the longest-lasting pain treatments currently available. The company’s lead investigational product candidate, ATX101, is currently being evaluated in a Phase 2 clinical study in TKA surgeries. Allay unites a dynamic, global team of entrepreneurs, scientists, clinicians and innovators in the San Francisco Bay Area and Singapore.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Sonoma Biotherapeutics is a company invloved the development of adoptive Treg therapies cell for autoimmune and degenerative diseases. Using next generation genome editing and target-specific cell therapy, Sonoma is focused on developing its best-in-class platform across the entire spectrum of Treg cell therapeutic capabilities. Founded by pioneers in Treg biology and cell therapy, the company brings together leading expertise and proprietary methodologies for the discovery and development of disease modifying and curative therapies.

NeuSpera Medical develops implantable medical device technology to treat chronic illnesses through minimally invasive solutions. NeuSpera focuses on bioelectronic medicine and has developed ultra-miniaturized implants using their proprietary Mid-Field Powering technology. This technology allows the implants to be powered externally, enabling deeper and more reliable neuromodulation treatments for conditions like Urinary Urgency Incontinence (UUI) and chronic peripheral nerve pain

Boundless Bio is a company that develops novel cancer therapeutics intended to understand and treat untraceable cancers. It aims to be the biopharma company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable cancers.

Elevation Oncology makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Its lead candidate, seribantumab, which inhibits tumor growth driven by NRG1 fusions, is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion.

Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.The company's biotechnology platform integrates technologies and insights from scientific leaders all over the world in the fields of glycoscience and human immunology to create a novel approach to treating cancer by targeting multiple immune cell types, providing physicians with a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.

Elevation Oncology makes genomic tests actionable by selectively developing drugs to inhibit the specific alterations that have been identified as drivers of disease. Its lead candidate, seribantumab, which inhibits tumor growth driven by NRG1 fusions, is currently being clinically tested in the Phase 2 CRESTONE study for patients with tumors of any origin that have an NRG1 fusion.

Epirium Bio is a biopharmaceutical company based in San Diego, is developing a small molecule platform targeting improvements in muscle strength, tissue regeneration, and mitochondrial function.

BlackThorn Therapeutics operator of a clinical-stage biopharmaceutical company intended to develop precision medicine for disorders of the central nervous system (CNS) based on advances in computational and clinical neuroscience. The company leverages a deep understanding of brain and behavior relationships that seeks to overcome historic challenges in drug discovery and development by targeting dysfunctional brain circuits. Its proprietary computational platform, the company seeks to identify novel targets, small molecule drug candidates and biologically-based patient subgroups most likely to respond to treatment.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.

Twentyeight-Seven Therapeutics is a developer of microRNAs designed to target regulatory proteins.The company's modulating RNA which are short non-coding RNAs that inhibit target gene expression by suppressing mRNA translation and promoting mRNA decay and develop small molecules that can modulate levels of miRNAs by targeting proteins that interact with these miRNAs, enabling users to target miRNAs are directly involved in cancer initiation, progression, and metastasis.

Bicycle Therapeutics is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops which stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical need. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC.

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy to every patient with cancer.The company's next-generation cell and gene therapies with pharmacologic operating systems provide exquisite control of protein activity in cells and create adoptive cell therapies with new functions that are under control of the treating physician using simple, safe, orally-active, marketed drugs, enabling patients to improve on the current generation of cell therapies.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Palleon Pharmaceuticals is a developer of a biotechnology platform designed to offer glycoimmune checkpoint inhibitors to treat cancer.The company's biotechnology platform integrates technologies and insights from scientific leaders all over the world in the fields of glycoscience and human immunology to create a novel approach to treating cancer by targeting multiple immune cell types, providing physicians with a wider range of rational combination therapies to treat cancer and tackle resistance to first-generation immuno-oncology agents.

Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.

Innoventure is a startup medical device accelerator which brings US/EU medtech assets to China and get through the local regulatory path to develop further value.

Earlens is a privately held medical technology company committed to transforming the hearing experience for millions of people who suffer from hearing loss. The company has developed the Earlens Contact Hearing Solution, which directly activates natural hearing, delivering the broadest bandwidth available today and superior sound quality. This revolutionary, non-surgical hearing solution uses a small lens to vibrate the eardrum, replicating the natural hearing process. The Earlens Contact Hearing Solution received FDA clearance in 2019 for a second generation of the Earlens technology. Unlike traditional hearing aids, which are in effect tiny speakers that simply turn up the volume on air conducted sound, the Earlens Contact Hearing Solution™ is the world’s first to deliver sound directly to the eardrum.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Kona Medical is committed to alleviating the suffering and health risks associated with drug-resistant hypertension with a more effective, less invasive approach to renal artery denervation. The company was founded in 2009 by Michael Gertner, MD, with seed financing from Essex Woodlands. Kona was formed on the basis of combining Dr. Gertner’s inventions in the field with the assets of Therus Corporation, a predecessor company in the field of therapeutic focused ultrasound.

Moximed focuses on enhancing care for patients suffering from osteoarthritis, particularly through the MISHA Knee System. This system offers an outpatient treatment option for those who have not found relief from other therapies and are not candidates for knee replacement. The company aims to improve patients' quality of life by addressing their specific needs and challenges.

Twelve manufactures medical devices. It was formerly known as Foundry Newco XII, Inc. The company was incorporated in 2009 and is based in Menlo Park, California.

Visterra, Inc. engages in pharmaceutical drug research and development of therapeutic and diagnostic products for infectious diseases. It also provides structure-based design of therapeutics and diagnostic platforms, based on an understanding of glycobiology and glycochemistry. The company was formerly known as Parasol Therapeutics, Inc. and changed its name in May 2010. Visterra, Inc. was founded in 2007 and is based in Cambridge, Massachusetts.

Ivantis, Inc. is a company focused on developing an innovative treatment for Glaucoma. It is their goal to develop a less invasive, more effective option for the 60+ million people worldwide suffering from Primary Open Angle Glaucoma. As they successfully address this initial goal, it is then there intention to focus on innovative development for the treatment of other debilitating diseases within ophthalmology.

Nuvaira is a new alternative COPD treatment option that specializes in developing devices for treating lung diseases. Nuvaira is currently working on a novel catheter-based system that has the potential to improve lung function, exercise capacity, and quality of life for patients with chronic obstructive pulmonary disease. It was founded in 2008 and headquartered in Minneapolis, Minnesota.

Sensimed designs, develops, and commercializes integrated micro-systems for medical devices. The company’s product portfolio includes SENSIMED Triggerfish, a product that offers an automated recoding of continuous ocular dimensional change over 24 hours. Sensimed is now focused on expanding the knowledge of how this individual data can best be used in the clinical setting to deliver customized treatment. The 24 hour profiles are being centralized on a registry together with patient and treatment information. The data is being analyzed and modeled on an ongoing basis in an attempt to identifying pathological patterns that can be used to differentiate indication, personalize treatment and assess efficacy following treatment. Sensimed was founded by Matteo Leonardi and Sacha Cerboni in August 2003 and is based in Lausanne, Switzerland.